248 related articles for article (PubMed ID: 19952744)
41. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
[TBL] [Abstract][Full Text] [Related]
42. Optimal surgical debulking in uterine papillary serous carcinoma affects survival.
Patsavas K; Woessner J; Gielda B; Rotmensch J; Yordan E; Bitterman P; Guirguis A
Gynecol Oncol; 2011 Jun; 121(3):581-5. PubMed ID: 21440290
[TBL] [Abstract][Full Text] [Related]
43. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
Fader AN; Starks D; Gehrig PA; Secord AA; Frasure HE; O'Malley DM; Tuller ER; Rose PG; Havrilesky LJ; Moore KN; Huh WK; Axtell AE; Kelley JL; Zanotti KM;
Gynecol Oncol; 2009 Nov; 115(2):244-8. PubMed ID: 19712966
[TBL] [Abstract][Full Text] [Related]
44. Uterine papillary serous carcinoma.
Moore KN; Fader AN
Clin Obstet Gynecol; 2011 Jun; 54(2):278-91. PubMed ID: 21508697
[TBL] [Abstract][Full Text] [Related]
45. Early stage uterine serous carcinoma: management updates and genomic advances.
Fader AN; Santin AD; Gehrig PA
Gynecol Oncol; 2013 Apr; 129(1):244-50. PubMed ID: 23321062
[TBL] [Abstract][Full Text] [Related]
46. Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
Obermair A; Mileshkin L; Bolz K; Kondalsamy-Chennakesavan S; Cheuk R; Vasey P; Wyld D; Goh J; Nicklin JL; Perrin LC; Sykes P; Janda M
Gynecol Oncol; 2011 Feb; 120(2):179-84. PubMed ID: 21126755
[TBL] [Abstract][Full Text] [Related]
47. The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 1999 Aug; 74(2):272-7. PubMed ID: 10419744
[TBL] [Abstract][Full Text] [Related]
48. Survival outcomes of adjuvant radiotherapy and chemotherapy in women with stage I serous papillary and clear cell carcinoma of the endometrium: a Korean multicenter study.
Kim M; Kwon BS; Chang HK; Lee S; Chang SJ; Choi JY; Park SY; Lee M; Ryu HS; Kim YB
J Gynecol Oncol; 2019 May; 30(3):e44. PubMed ID: 30887761
[TBL] [Abstract][Full Text] [Related]
49. The management of serous papillary uterine cancer.
Schwartz PE
Curr Opin Oncol; 2006 Sep; 18(5):494-9. PubMed ID: 16894299
[TBL] [Abstract][Full Text] [Related]
50. Clear-cell and papillary serous cancer: treatment options.
Tropé C; Kristensen GB; Abeler VM
Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):433-46. PubMed ID: 11476564
[TBL] [Abstract][Full Text] [Related]
51. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma.
Rosenberg P; Blom R; Högberg T; Simonsen E
Gynecol Oncol; 1993 Dec; 51(3):311-5. PubMed ID: 8112638
[TBL] [Abstract][Full Text] [Related]
52. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
Kwon JS; Abrams J; Sugimoto A; Carey MS
Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450
[TBL] [Abstract][Full Text] [Related]
53. Cervical cytology in serous and endometrioid endometrial cancer.
Roelofsen T; Geels YP; Pijnenborg JM; van Ham MA; Zomer SF; van Tilburg JM; Snijders MP; Siebers AG; Bulten J; Massuger LF
Int J Gynecol Pathol; 2013 Jul; 32(4):390-8. PubMed ID: 23722512
[TBL] [Abstract][Full Text] [Related]
54. Clinico-cytological study of uterine papillary serous carcinoma.
Hagiwara T; Kaku T; Kobayashi H; Hirakawa T; Nakano H
Cytopathology; 2005 Jun; 16(3):125-31. PubMed ID: 15924607
[TBL] [Abstract][Full Text] [Related]
55. [Uterine papillary serous carcinoma--one kind of special type of uterine endometrial carcinoma].
Wu M; Lang J; Guo L
Zhonghua Fu Chan Ke Za Zhi; 1996 Jan; 31(1):3-7. PubMed ID: 8758809
[TBL] [Abstract][Full Text] [Related]
56. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma.
Fader AN; Drake RD; O'Malley DM; Gibbons HE; Huh WK; Havrilesky LJ; Gehrig PA; Tuller E; Axtell AE; Zanotti KM;
Cancer; 2009 May; 115(10):2119-27. PubMed ID: 19306417
[TBL] [Abstract][Full Text] [Related]
57. Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
Peled Y; Aviram A; Krissi H; Gershoni A; Sabah G; Levavi H; Eitan R
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):498-502. PubMed ID: 26235227
[TBL] [Abstract][Full Text] [Related]
58. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.
Hamilton CA; Liou WS; Osann K; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):839-44. PubMed ID: 16199314
[TBL] [Abstract][Full Text] [Related]
59. The prognostic significance of thrombocytosis in uterine papillary serous carcinomas.
Lerner DL; Walsh CS; Cass I; Karlan BY; Li AJ
Gynecol Oncol; 2007 Jan; 104(1):91-4. PubMed ID: 16934317
[TBL] [Abstract][Full Text] [Related]
60. Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer.
Martin JD; Gilks B; Lim P
Gynecol Oncol; 2005 Aug; 98(2):299-303. PubMed ID: 15964062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
